Amylyx CEO Klee Vests 60,000 Shares via Zero‑Price PSUs as Clinical Milestones Drive Insider Confidence
Insider buying spree at Amylyx Pharma shows CEO Klee’s confidence in avexitide’s NDA success, hinting at a short‑term rally for investors.
4 minutes to read



